arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

VERTEX PHARMACEUTICALS INC / MA

VRTX
$516.08 ▲ +1.02 (+0.20%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

VERTEX PHARMACEUTICALS INC / MA shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $130.9B
Dividend Yield
Revenue Growth 12.5%
Op. Margin 37.4%
ROIC 4.9%
FCF / Share $3.99
Trailing P/E 118.9x
Price / Book 6.5x
FCF Yield 0.8%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.33B
↑ +12.5%
Net Income Profit after all expenses
$1.10B
↑ +6.5%
Operating Margin Operating profit as % of sales
37.4%
↓ -1.8% 90th
FCF / Share Free cash flow per share
$3.99
↓ -21.6%
Long-Term Debt Long-term obligations
$105.00M
— 0.0%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
91
Returns
87
Financial Health
97
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters